MEK1 gene mutation in Japanese lung adenocarcinoma patients

Molecular Medicine Reports

Volumn 2, Issue 2, 2009, Pages 153-155

  Sasaki, Hidefumi ^a,b   Hikosaka, Yu ^a   Okuda, Katsuhiro ^a   Kawano, Osamu ^a   Yukiue, Haruhiro ^a   Yano, Motoki ^a   Fujii, Yoshitaka ^a  

^a NAGOYA CITY UNIV MEDICAL SCHOOL   (Japan)

^b Department of Surgery II ^*  (Japan)

Author keywords

Epidermal growth factor receptor; Exon 2; K57N; Lung adenocarcinoma; MEK1

Indexed keywords

B RAF KINASE; EPIDERMAL GROWTH FACTOR RECEPTOR; K RAS PROTEIN; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; MITOGEN ACTIVATED PROTEIN KINASE KINASE 1;

ADULT; AGED; ARTICLE; CANCER PATIENT; CANCER STAGING; CANCER SURGERY; EXON; FEMALE; GENE; GENE MUTATION; GENE SEQUENCE; GENETIC ANALYSIS; HUMAN; JAPANESE; LUNG ADENOCARCINOMA; MAJOR CLINICAL STUDY; MALE; MITOGEN ACTIVATED PROTEIN KINASE KINASE 1 GENE; ONCOGENE K RAS; SOMATIC MUTATION; UNIVERSITY HOSPITAL;

EID: 69249104989     PISSN: 17912997     EISSN: 17913004     Source Type: Journal    
DOI: 10.3892/mmr_00000076     Document Type: Article

References (23)

1. Ginsberg RJ, Kris K and Armstrong G: Cancer of the lung. In: Principles and Practice of Oncology. 4th edition, Lippincott, Philadelphia, pp673-682, 1993.
2. Yasuda K, Ayabe H, Ide H and Uchida Y: On behalf of the Japanese Association for Thoracic Surgery: Thoracic and cardiovascular surgery in Japan during 1998. Annual report by the Japanese Association for Thoracic Surgery. Jpn J Cardiothorac Surg 48: 401-415, 1998.
3. Kyriakis JM, App H, Zhang XF, et al: Raf-1 activates MAP kinase-kinase. Nature 358: 417-421, 1992.
4. Shama J, Garcia-Medina R, Pouyssegur J and Vial E: Major contribution of MEK1 to the activation of ERK1/ERK2 and to the growth of LS174T colon carcinoma cells. Biochem Biophys Res Commun 372: 845-849, 2008.
5. Rodriguez-Viciana P, Tetsu O, Tidyman WE, et al: Germline mutations in genes within the MAP pathway cause cardio-faciocutaneous syndrome. Science 3: 1287-1290, 2006. (Pubitemid 43334718)
6. Rodriguez-Viciana P and Rauen KA: Biochemical characterization of novel germline BRAF and MEK mutations in cardio-faciocutaneous syndrome. Methods Enzymol 438: 277-289, 2008.
7. Senawong T, Phuchareon J, Ohara O, McCormick F, Rauen KA and Tetsu O: Germline mutations of MEK in cardio-faciocutaneous syndrome are sensitive to MEK and RAF inhibition: implications for therapeutic options. Hum Mol Genet 17: 419-430, 2008.
8. Marks JI, Gong Y, Chitale D, et al: Novel MEK1 mutation identified by mutational analysis of epidermal growth factor receptor signaling pathway genes in lung adenocarcinoma. Cancer Res 68: 5524-5528, 2008.
9. Bottorff D, Stang S, Agellon S and Stone JC: RAS signaling is abnormal in a c-raf1 MEK1 double mutant. Mol Cell Biol 15: 5113-5122, 1995.
10. Estep AL, Palmer C, McCormick F and Rauen KA: Mutation analysis of BRAF, MEK1 and MEK2 in 15 ovarian cancer cell lines: implications for therapy. PLoS ONE 2: e1279, 2007.
11. Paez JG, Janne PA, Lee JC, et al: EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 304: 1497-1500, 2004. (Pubitemid 38720929)
12. Endo K, Konishi A, Sasaki H, et al: Epidermal growth factor receptor gene mutation in non-small cell lung cancer using highly sensitive and fast TaqMan PCR assay. Lung Cancer 50: 375-384, 2005. (Pubitemid 43300637)
13. Sasaki H, Shimizu S, Endo K, et al: EGFR and erbB2 mutation status in Japanese lung cancer patients. Int J Cancer 118: 180-184, 2006. (Pubitemid 41681596)
14. Sasaki H, Endo K, Konishi A, et al: EGFR mutation status in Japanese lung cancer patients: genotyping analysis using LightCycler. Clin Cancer Res 11 : 2924-2929, 2005. (Pubitemid 40525194)
15. Sasaki H, Kawano O, Endo K, et al: Uncommon V599E BRAF mutations in Japanese patients with lung cancer. J Surg Res 133: 203-206, 2006. (Pubitemid 41681596)
16. Sasaki H, Okuda K, Kawano O, et al: Nras and Kras mutation in Japanese lung cancer patients: Genotyping analysis using LightCycler. Oncol Rep 18: 623-628, 2007.
17. Mansour SJ, Matten WT, Hermann AS, et al: Transformation of mammalian cells by constitutively active MAP kinase kinase. Science 265: 966-970, 1994. (Pubitemid 24281496)
18. Sebolt-Leopold JS, Dudley DT, Herrera R, et al: Blockade of the MAP kinase pathway suppress growth of colon tumors in vivo. Nat Med 5: 810-816, 1999. (Pubitemid 29318616)
19. Marks JL, McLellan MD, Zakowski MF, et al: Mutational analysis of EGFR and related signaling pathway genes in lung adenocarcinomas identifies a novel somatic kinase domain mutation in FGFR4. Prot PLosS ONE 2: e426, 2007.
20. Schulz AL, Alberecht B, Arici C, et al: Mutation and phenotypic spectrum in patients with cardio-ficio-cutaneous and Costello syndrome. Clin Genet 73: 62-70, 2008. (Pubitemid 350263523)
21. Bisogno G, Murgis A, Mimmi I, Strafella MS and Carli M: Rhabdomyosarcoma in a patient with cardio-facio-cutaneous syndrome. J Pediatr Hematol Oncol 21: 424-427, 1999.
22. Al-Rahawan MM, Chute DJ, Sol-Church K, et al: Hepatoblastoma and heart transplantation in a patient with cardio-facio-cutaneous syndrome. Am J Med Genet A 143: 1481-1486, 2007. (Pubitemid 47051027)
23. Makita Y, Narumi Y, Yoshida M, et al: Leukemia in Cardio-facio-cutaneous (CFC) syndrome: a patient with a germline mutation in BRAF proto-oncogene. J Pediatr Hematol Oncol 29: 287-290, 2007. (Pubitemid 46707505)